Tag: collaborations

What you need to know:

Hangzhou, China, June 24, 2025 (GLOBE NEWSWIRE) --

As smart advances through 2025 - the year of enhancing global operation – the premium electric automotive brand continues to drive innovation across global markets through strategic partnerships and product excellence. In the first half of 2025, smart has made significant inroads into the global market landscape, successfully entering seven new markets across the MENA region and Latin America. The business footprint has now expanded to 38 countries and regions, with exceeding 580 stores worldwide. 

Paris, June 24, 2025 — Docugami, the fast-growing U.S. startup specializing in Document AI, announces the launch of Docugami Europe, its new subsidiary based in France. This move marks a strategic investment in the European innovation landscape and reinforces Docugami’s commitment to advancing open, transparent, and sovereign AI.

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.